Keith Robison has a perceptive piece riffing off the recent Illumina instrument launch, and ponders whether 2010 will be the year that array-based genomic technologies finally start to die off with the rise of sequencing.
The market certainly seems to think so. Check out the immediate effect on stock prices for Illumina (ILMN) and array manufacturer Affymetrix (AFFX) following the Illumina announcement (both normalised to 0 at the start of the graph):
This comes in the context of long-term stagnation of AFFX stock, while Illumina has exploded over the last five years. Illumina made plenty of money from the array market, but it also established itself as a key player in the emergence of next-generation sequencing. Affymetrix was not as far-sighted.
More like this
Join Illumina in its quest to discover "What makes you... you?" And to discern why even though people are genetically 99.9 % similar, we look and act so incredibly different!
Two days ago I reported a rumour that the FDA might have convinced genotyping chip provider Illumina to stop providing its products to direct-to-consumer genetic testing companies - a move that would ef
I notice that Fortune has a story on personal genomics up, Genetic sequencing gets personal Biotech firm Illumina will sequence your entire genetic code -- and throw i
Update 14:35 EDT 04/08/10: I just received a phone call from a 23andMe representative indicating that these rumours are not true; more details to follow once I have a written statement.
We're moving away from microarrays for gene expression and shifting efforts to using next gen sequencing instead.
To the extent that I don't believe we're planning on printing any more of our arrays and will just exhaust our current supply for collaborators.